Lysyl oxidase-like 2 (LOXL2), a secreted enzyme that catalyzes the cross-linking of collagen, plays an essential role in developmental angiogenesis. We found that administration of the LOXL2-neutralizing antibody AB0023 inhibited bFGF-induced angiogenesis in Matrigel plug assays and suppressed recruitment of angiogenesis promoting bone marrow cells. Small hairpin RNAmediated inhibition of LOXL2 expression or inhibition of LOXL2 using AB0023 reduced the migration and network-forming ability of endothelial cells, suggesting that the inhibition of angiogenesis results from a direct effect on endothelial cells. To examine the effects of AB0023 on tumour angiogenesis, AB0023 was administered to mice bearing tumours derived from SKOV-3 ovarian carcinoma or Lewis lung carcinoma (LLC) cells. AB0023 treatment significantly reduced the microvascular density in these tumours but did not inhibit tumour growth. However, treatment of mice bearing SKOV-3-derived tumours with AB0023 also promoted increased coverage of tumour vessels with pericytes and reduced tumour hypoxia, providing evidence that anti-LOXL2 therapy results in the normalization of tumour blood vessels. In agreement with these data, treatment of mice bearing LLC-derived tumours with AB0023 improved the perfusion of the tumourassociated vessels as determined by ultrasonography. Improved perfusion and normalization of tumour vessels after treatment with anti-angiogenic agents were previously found to improve the delivery of chemotherapeutic agents into tumours and to result in an enhancement of chemotherapeutic efficiency. Indeed, treatment with AB0023 significantly enhanced the anti-tumourigenic effects of taxol. Our results suggest that inhibition of LOXL2 may prove beneficial for the treatment of angiogenic tumours.
Introduction
Lysyl oxidase-like 2 (LOXL2) is a member of a family of lysyl oxidase enzymes that contribute to the synthesis and stabilization of extracellular matrices by catalyzing the formation of covalent bonds that link lysine residues of neighbouring fibrils of collagen type I and elastin (1) . LOXL2 was initially identified as an upregulated gene in Werner's syndrome (2) and was subsequently found to enhance tumour invasion and to induce tumoural and hepatic fibrosis (3, 4) . Over-expression of LOXL2 is associated with aggressive breast cancer (3), colon cancer (5) , gastric cancer (6) and skin cancer (7) . There is evidence that LOXL2 promotes tumour progression using several concurrent mechanisms that include induction of epithelial to mesenchymal transition, either by oxidation of intracellular targets by intracellular LOXL2 (8) (9) (10) (11) or by effects that are transduced from the extracellular environment (12) . Recent evidence demonstrates that LOXL2 is over-expressed in a wide variety of solid tumours and suggests that increased local tension resulting from LOXL2-mediated cross-linking of collagen may promote tumour progression (12, 13) . In addition, it was found that hydrogen peroxide formed as a by-product of the activity of lysyl oxidases can also induce tumour cells invasiveness (14) . In agreement with these observations, we have recently found that the LOXL2-inhibiting monoclonal antibody AB0023 has anti-tumourigenic and anti-fibrotic effects (12) . Supported by these preclinical data, a humanized version of AB0023, simtuzumab, is currently being evaluated in clinical trials for the treatment of advanced solid tumours.
Tumour cells interact with a variety of stromal cells in their local micro-environment, including fibroblasts and endothelial cells (15) . Tumour cells, as well as tumour-associated stromal cells, secrete angiogenic factors that induce the proliferation and migration of endothelial cells from pre-existing blood vessels. These endothelial cells form angiogenic sprouts that eventually invade the tumour to form a tumour-associated network of blood vessels that are essential for the delivery of nutrients and oxygen required for tumour growth (16) . The extracellular matrix (ECM) plays a key role in the success of this neovascularization as newly formed endothelial cell sprouts use an ECM scaffold to migrate and establish new functional vessels (17) . LOXL2 is expressed in endothelial cells and contributes to the synthesis of elastic fibres that are associated with blood vessels (18) . The expression of LOXL2 is upregulated in hypoxic conditions and contributes to the hypoxia-induced deposition of basement membrane collagen IV, suggesting that it plays a role in angiogenesis (19, 20) . Indeed, it was recently observed that LOXL2 has an essential role in developmental angiogenesis and that zebrafish embryos lacking LOXL2 expression fail to form normal intersegmental blood vessels (20) .
We have previously observed that LOXL2 protein expression is specifically upregulated in tumour endothelial cells and that a neutralizing antibody directed against LOXL2 causes a reduction in the concentration of tumour-associated endothelial cells (12) . In this work, we sought to characterize in greater detail the effects of LOXL2 on tumour angiogenesis. We find that inhibition of LOXL2 using the inhibitory antibody AB0023 (21) inhibits tumour angiogenesis in highly angiogenic tumours derived from ovarian carcinoma and lung carcinoma cells. In both models, the inhibition was not sufficient to inhibit tumour development by itself. However, the inhibition induced the normalization of tumour-associated blood vessels (22) and promoted enhanced sensitivity to treatment by the chemotherapeutic agent taxol.
Materials and methods

Reagents and cells
Human umbilical vein endothelial cells (HUVEC) were isolated from umbilical veins (23) and were cultured as described (24) . SKOV-3, Lewis lung carcinoma (LLC), MCF-7, HEK293 and HEK-293T cells were from ATCC and were prepared under standard growth conditions. Matrigel for in vitro and in vivo assays was from Becton Dickinson. Recombinant human bFGF for HUVEC A role for LOXL2 in tumour angiogenesis assays was produced and purified as described (25) . Recombinant human vascular endothelial growth factor (VEGF) 165 was produced as described previously (26) . Hyaluronidase and horseradish peroxidase were from SigmaAldrich. Collagenases 3 and 4 were from Worthington Biochemical Corp. Dispase II was from Roche. AC-1 monoclonal IgG1 control antibody was from Antibody Solutions. The anti-LOXL2 monoclonal antibody M3 was generated in-house. The anti-LOX2 monoclonal antibody AB0023 was also generated in-house and was described previously (21) . An in-house anti-LOXL2 polyclonal antibody was also described previously (3) . Rat anti-mouse CD31 antibody for immunofluorescence experiments was from BD Pharmingen. Antibodies for flow cytometry against CD31, VEGFR-2 and CD45 were from Becton Dickinson, and antibodies against NG2 were from Chemicon International. Anti-CD34, -CD31 and -NG2 antibodies used in Matrigel plug analysis, the anti-CD31 antibody used in SKOV-3 and human tumour immunohistochemistry (IHC) and the anti-CA9 antibody used in SKOV-3 analysis were from Abcam. Cy2-and Cy3-labelled anti-rat antibodies were from Jackson Immunoresearch Laboratories. Human primary ovarian adenocarcinoma tissue was obtained from Cureline.
Inhibition of LOXL2 expression using small hairpin RNA and small interfering RNA The production of lentiviruses directing expression of small hairpin RNAs (shRNAs) used to inhibit LOXL2 expression was described previously (9) .
Western blotting
Protein lysates derived from lentivirus-infected HUVEC or LLC, SKOV-3, MCF-7 cells expressing empty vector, LOXL2, LOXL3 or HEK293 cells expressing LOXL4 were subjected to sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Gels were transferred to nitrocellulose membranes, which were then probed with the anti-LOXL2 rabbit polyclonal antibody or with the M3 anti-LOXL2 monoclonal antibody that recognizes both mouse and human LOXL2 according to standard procedures. Equal protein loading was assessed using an antibody directed against β-actin or vinculin.
Transwell migration and tube formation assays
For migration assays, HUVEC were seeded in transwell culture dishes (8 µm pores, 3 × 10 4 cells/well) coated with fibronectin (10 µg/ml, Biological Industries) in 200 µl of M199 medium containing 10% fetal calf serum and 10 μg/ml AB0023 (21) or 10 µg/ml of the non-targeting control antibody AC-1 in the presence of bFGF (5 ng/ml) or VEGF 165 (10 ng/ml). After 5 h, migrated cells were fixed for 20 min with 4% paraformaldehyde, washed thrice with phosphate-buffered saline (PBS), stained with 0.05% crystal violet for 10 min, photographed and counted. Tube formation on Matrigel was carried out as described (27) . Briefly, shLOXL2 or control shRNA-infected HUVEC or native HUVEC were seeded in Matrigelcoated 48-well tissue culture plates (1.6 × 10 4 cells/well) and incubated with growth medium supplemented with bFGF (5 ng/ml) and 1 µg/ml AB0023 or 1 µg/ ml AC-1 for 24 h. Phase-contrast images of tubes were taken after 2, 4, 6 and 24 h at a ×10 magnification and bifurcations per microscopic field counted.
Matrigel plug angiogenesis assays
Monoclonal antibodies (AB0023 or non-targeting AC-1) or PBS containing 0.02% Tween 20 vehicle (0.01% Tween 20 in PBS) were injected intraperitoneally (30 mg/kg or equivalent volume) twice weekly into athymic female Ncr:Nu/Nu mice. After 1 week, the mice were injected subcutaneously with 250 or 500 µl Matrigel (BD Biosciences) supplemented with 100 ng/ml human bFGF (Peprotech) and 40 or 60 U heparin (Sigma). Matrigel plugs were harvested after 10 days, excised together with attached skin, fixed in 10% neutral buffered formalin and embedded in paraffin. Immunohistochemical analysis was performed on 5-μm serial sections with anti-CD31, anti-CD34 and anti-NG2 antibodies. The solutions used for the IHC protocols were obtained from BioCareMedical. All procedures were performed at room temperature. Five-micrometer sections of frozen tissue were fixed with 4% paraformaldehyde. Antigen retrieval methods were followed on formalin fixed tissues (5 μm) using a decloaking chamber at 90°C for 45 min, and subsequent IHC was performed. The endogenous peroxidase was blocked with Peroxidazed-1 and the background blocked with Background Sniper. Primary antibody incubations were performed for 30 min. Mach2 rabbit polymer was used for primary antibody detection, the chromagen was developed with 3,3′-diaminobenzidine and the slides were counter-stained with haematoxylin, followed by dehydration with graded alcohol. The slides were mounted with Entellan mounting media (Electron Microscopy Sciences). Two-step sections separated by 800 µM were analyzed per plug. Three representative ×10 microscopic fields were selected per section per step, for a total of six fields per plug. In the second study, which included the AC-1 treatment group, immunohistochemical analysis was performed with anti-CD34 antibody on one representative section for each plug. Three representative ×10 fields were selected per section for quantification. For all IHC analysis of plugs, the mean area of signal was determined for each treatment group using Metamorph software (Molecular Devices).
Analysis of cell populations in Matrigel plugs
Matrigel plugs containing bFGF were implanted in the flanks of mice as described above. One group was injected thrice per week with 30 mg/kg of AB0023 antibody and the other group with vehicle (PBST). Following excision of the plugs 7 days after inoculation, intra-plug cells were recovered and subjected to FACS analysis (CyAn ADP Beckman Coulter) essentially as described (28) . Briefly, Matrigel plugs were incubated twice for 15 min at 37°C on a shaker in PBS containing 25 mg/ml hyaluronidase, 25 mg/ml collagenase-3, 50 mg/ml collagenase-4 and 250 mg/ml Dispase II to liberate cells from plugs. Aliquots were incubated with antibodies, washed with FACS buffer (0.2% bovine serum albumin, 0.3% ethylenediaminetetraacetic acid in PBS) and subjected to FACS analysis.
Evaluation of microvascular density, pericyte coverage, hypoxia and vessel perfusion in frozen tumour sections A total of 5 × 10 6 SKOV-3 ovarian carcinoma cells were implanted subcutaneously in female athymic nude mice in 50% vol/vol Matrigel. After tumours attained a volume of approximately 100 mm 3 , the mice received twice weekly intraperitoneal injections of vehicle, AB0023 antibody (15 mg/kg), taxol (5 mg/kg) or injection of both taxol and AB0023. The animals were killed 42 days after treatment initiation, and 5 µm frozen sections were prepared from snap-frozen tumours. Sections were fixed with 4% paraformaldehyde and blocked using Peroxidazed 1 and Background Sniper (Biocare Medical) before primary antibody incubation. Anti-CA9 antibody (Abcam) was applied and Mach2 HRP-polymer (Biocare Medical) was used as secondary antibody. All sections were dehydrated through a series of ethanol dilutions and xylene, mounted using a resinous medium and visualized using 3,3′-diaminobenzidine chromagen. For the vessel perfusion experiment, the animals were injected intravenously with Hoechst 33342 (40 mg/kg) 1 min prior to the sacrifice, and tumour removal was performed as described (29, 30) . The 15-µm frozen tumour sections were fixed in acetone for 10 min, blocked with PBS containing 10% bovine serum albumin and incubated with antibodies directed against NG2 or CD31. Bound CD31 antibodies were detected with goat anti-rat CY3-labelled antibodies, and bound NG2 antibodies were detected with anti-rabbit Cy2-labelled antibodies. The stained sections were visualized using a confocal microscope or a Leica CTR 6000 microscope. At least five microscopic fields were analyzed in each section. For analysis of perfusion, numbers of CD31-expressing vessels coinciding with Hoechst dye fluorescence were counted in each field. For the association of pericytes and vessels, the area of NG2-stained cells in association with CD31-stained vessels was determined using the ImagePro morphometric software (31) (Media Cybernetics).
To generate LLC-derived tumours, LLC cells (1 × 10 6 cells) were implanted subcutaneously in female athymic nude mice. The mice received intraperitoneal injections of AC-1 or AB0023 antibody (15 mg/kg) twice weekly. Mice were killed after 21 days. The evaluation of the microvascular density in these tumours was done as described above for SKOV-3 tumours.
IHC analysis of SKOV-3 and LLC tumours
Fresh frozen tissues were embedded in molds with OCT compound and then submerged in an isopentane dry ice bath (−78°C) for greater than 1 min. Tissues were then retrieved, and wrapped in foil and stored at −80°C. To prepare for sectioning, tissues were equilibrated to −20°C in the cryostat (Leica CM1850) for approximately 1 h. Five-micrometer-thick cryosections were cut and transferred onto SuperFrost positively charged slides. Slides were dried for 24 h and then stained or stored at −80°C. All IHC reagents and equipment were from Biocare Medical, unless otherwise stated. IHC procedures were performed at room temperature unless otherwise stated, and all slides were stained (post-fixation) using the Nemesis 3600 from Biocare Medical. Slides were fixed with 4% paraformaldehyde (VWR) for 10 min and rinsed in 1× PBS containing 0.02% Tween 20 in preparation for IHC. Slides were treated with Peroxidazed for 15 min and blocked with Background Sniper for 20 min. Slides were incubated with primary antibody in Da Vinci Green Diluent for 30 min. Slides were then rinsed in tris-buffered saline-Autowash. The Mach 2 polymer kit was used for antigen detection by adding anti-rabbit secondary antibody (conjugated to horseradish peroxidase) for 30 min. 3,3′-Diaminobenzidine chromagen was added to the slides for 5 min followed by a single rinse in tris-buffered saline-Autowash followed by a single rinse in distilled water. The slides were then counter-stained with haematoxylin, followed by manual dehydration with graded alcohol. Lastly, slides were mounted with Entellan mounting media. All slides were visualized using a Leica microscope. Images were acquired using a Leica DFC500 camera and Leica DMLB light microscope with the Leica Application Suite (LAS), Version 4.0, or with the Leica Slide Scanner SCN400 and SCN400 client software. The digital images were documented by exporting to the Digital Image Hub (DIH-SlidePath).
Ultrasound
Ultrasound imaging of LLC-derived tumours was performed using the Vevo 2100 high-frequency ultrasound system (VisualSonics, Toronto, ON, Canada) as described (32) . Briefly, mice bearing LLC tumours S.Zaffryar-Eilot et al.
were anesthetized. A bolus injection of 70 µl (concentration of 2 × 10 9 microbubbles/ml) of the contrast agent (Vevo MicroMarker®; VisualSonics) was delivered into the tail vein by catheter for intravenous administration of the contrast agent. Ultrasound acoustic gel (Aquasonic 100, Parker Laboratories, Fairfield, NJ) and a solid state transducer (MS-250SC) were used to obtain images using non-linear Contrast Mode imaging. Nonlinear detection of the contrast signal was done in three dimensions by stepping the transducer through the volume of the tumour at a step size of 0.152 mm. Acquisition parameters were kept constant at 4% power, 28 dB contrast gain, gate size of 6, high line density and standard beam width. Tumour volume was determined by manually outlining the borders of the tumour in several images throughout the stack acquired in 3D scanning. The 2D dynamic analysis of contrast agent flow was performed by fitting a Destruction-Reperfusion curve model to the measured mean intensity values inside the region of interest. To reduce the user dependency of the results, the initial rise and the plateau time points were detected automatically at 10 and 90% of the fitted curve amplitude to generate peak enhancement values (P.E.) in dB units and in arbitrary units (a.u.) and time to peak values in seconds. The percent agent (PA) value was calculated using the Vevo 2100 3D software as the percentage of pixels within the defined volume, which has the non-linear contrast signal associated with them. Baseline PA values were acquired before contrast agent delivery and compared with PA value after delivery, while the contrast agent circulates through the subcutaneous tumour. A differential PA value was calculated by subtracting the baseline PA from the post-injection PA; this value was used as a measure of relative blood volume. The visualization of blood vessels inside the tumour was achieved by applying a non-linear filter and vesselness detector to the maximum intensity persistence image as will be described in a separate manuscript (Bar Zion et al., in preparation).
Statistical analysis
Statistical significance was determined using the unpaired Student's t-test, with or without Welch's correction for unequal variances as determined by the F-test, by ANOVA (GraphPad Prism software) or using the non-parametric Mann-Whitney U-test as indicated in the figure legends. *, ** and *** represent P < 0.05, P < 0.01 and P < 0.001, respectively. Error bars represent the standard error of the mean.
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Results
Inhibition of LOXL2 suppresses bFGF-induced migration and network assembly by endothelial cells
To determine whether LOXL2 contributes to bFGF-induced migration of HUVEC, we inhibited the expression of LOXL2 using previously reported LOXL2-targeting shRNAs ( Figure 1A ) (9) . shRNA-mediated silencing of LOXL2 expression in HUVEC significantly inhibited both bFGF and VEGF 165 -induced migration and the ability of these cells to form networks on Matrigel, in comparison with HUVEC expressing a control (non-targeting) shRNA ( Figure 1B, C and D) . We observed similar inhibitory effects using a small interfering RNA targeting LOXL2 and also with a lentivirus encoding a different LOXL2-targeting shRNA. The two shRNAs and the small interfering RNA were all directed against different sequences in the LOXL2 transcript (Supplementary Figure 1A -E, available at Carcinogenesis Online). Silencing of LOXL2 expression by shRNA did not affect cell viability compared with control shRNA as assessed by TUNEL staining (data not shown). Addition of 10 µg/ml of the previously characterized LOXL2-inhibiting monoclonal antibody AB0023 (12,21) significantly inhibited bFGF-induced cell migration ( Figure 1E ) and network assembly on Matrigel ( Figure 1F ). In contrast, although AB0023 inhibited VEGF-induced migration, the inhibition did not reach statistical significance (data not shown). Kinetic analysis of endothelial cell network assembly revealed that the impact of reducing or inhibiting LOXL2 was seen in the early stages of endothelial cell migration to form cell-cell contacts, as the greatest effect was observed within the first 2 h after plating.
AB0023 administration suppresses bFGF-induced angiogenesis in vivo
To determine whether inhibition of LOXL2 suppresses angiogenesis in vivo, we examined the effects of AB0023 on bFGF-induced angiogenesis using the Matrigel plug assay (33, 34) . In three independent assays, AB0023 (30 mg/kg), vehicle control or a control non-related antibody (AC-1) was delivered by intraperitoneal injection to mice implanted with bFGF-containing Matrigel plugs. Administration of AB0023 resulted in a reduction in infiltrating vessels observed in plugs harvested after 10 days (Figure 2A ). This effect was quantified in two independent experiments by measuring the relative area of intra-plug cells expressing the endothelial cell markers CD31 or CD34 or the pericyte marker NG2 (Figure 2B and C) . Although none of these markers are expressed exclusively in vascular-associated cells, visual inspection confirmed that the majority of immunoreactivity was restricted to infiltrating vessels (Supplementary Figure 2C , available at Carcinogenesis Online). Immunohistochemical staining in subcutaneous tissue adjacent to Matrigel plugs demonstrated the specificity of the anti-CD31 and anti-NG2 antibodies (Supplementary Figure 2C , available at Carcinogenesis Online). AB0023 treatment also significantly reduced the number of blood vessels as assessed by manual counting of plug section composites (Supplementary Figure  2A and B, available at Carcinogenesis Online). In an independent Matrigel plug assay, we assessed the anti-angiogenic effects of systemic AB0023 by utilizing FACS analysis to quantify cell populations expressing vascular markers in Matrigel plugs using a recently described method (28) . We found that intraperitoneal administration of AB0023 (30 mg/kg) significantly reduced the number of endothelial cells. Endothelial cells are presented either as CD31 positive ( Figure 2D ) or as cells positive for VEGFR-2 + and negative for CD45 (Supplementary Figure 3A, available at Carcinogenesis Online) present in plugs harvested 7 days after inoculation ( Figure 2D) . Regardless of the method of detection, we find that AB0023 reduces the concentration of cells defined by these endothelial cell markers in the Matrigel plugs. Interestingly, administration of AB0023 also significantly reduced the recruitment of myeloid-derived suppressor cells as presented by positive to Gr1 and CD11b ( Figure 2D ). These cells have been previously found to be recruited to tumours and to enhance tumour angiogenesis (35, 36) .
AB0023 administration normalizes tumour vasculature
To assess whether inhibition of LOXL2 affected the tumour vasculature, we chose the human SKOV-3 ovarian adenocarcinoma and the murine LLC xenograft tumour models. Both of these cell lines form highly vascularized non-desmoplastic subcutaneous tumours (37, 38) . Both of these cell types express LOXL2 as determined by western blot analysis of cell extracts ( Figure 3A) . We also characterized LOXL2 expression in SKOV-3 and in LLC-derived tumours by IHC. We found, by staining serial sections for CD31, that although a subpopulation of tumour cells expressed LOXL2, the majority of the LOXL2 was expressed by endothelial cells of tumour-associated blood vessels ( Figure 3B and C, arrows) . We have previously observed that LOXL2 is strongly expressed by activated fibroblasts in highly desmoplastic tumours (12) . However, even in the few areas in which we saw collagen-rich stroma in SKOV-3-derived tumours we could detect only few if any activated fibroblasts as assessed by staining for the activated fibroblast marker α-smooth muscle actin (Supplementary Figure 4B , available at Carcinogenesis Online). Interestingly, LOXL2 expression in tumour-associated blood vessels was also seen in metastases derived from human ovarian adenocarcinomas (Supplementary Figure 4A , available at Carcinogenesis Online). To determine whether AB0023 can interfere with tumour growth and progression, we administered AB0023 (15 mg/kg) intraperitoneally to SKOV-3 tumour-bearing mice twice weekly, once tumours reached an average size of 100 mm 3 . As a single agent, AB0023 treatment did not affect either SKOV-3 ( Figure 4A ) or LLC (data not shown) tumour growth. Immunohistochemical analysis of SKOV-3 and LLC tumour samples harvested 42 or 21 days after treatment initiation, respectively, revealed a statistically significant decrease in the concentration of tumour blood vessels, which was quantified by measuring the area of CD31-positive cells ( Figures 4B  and 6A) .
Treatment of mice bearing SKOV-3 tumours with 5 mg/kg taxol alone produced a modest, but not statistically significant, inhibition of SKOV-3 tumour growth ( Figure 4A ). In contrast, taxol co-administration with 15 mg/kg AB0023 achieved a statistically significantly reduction in tumour size in comparison with vehicle-treated tumours or to taxol only treated tumours ( Figure 4A ). We hypothesized that the AB0023 enhancement of the anti-tumourigenic effect of taxol may be due to normalization of the tumour vasculature (39) . Similar effects have been previously observed after administration of an antiangiogenic agent targeting VEGF (22) . Normalization of blood vessels is characterized by increased tumour perfusion, reduced tumour hypoxia, reduced leakiness of tumour blood vessels and increased coverage of tumour vessels with pericytes (39, 40) . We assessed intra-tumour hypoxia in SKOV-3 xenografts by immunohistochemical analysis of the expression of carbonic anhydrase-IX protein, an established marker for hypoxia (41) . We observed a significant 66% reduction in tumour carbonic anhydrase-IX levels in AB0023-treated tumours and a significant 32% reduction in the AB0023/taxol combination group ( Figure 4C ). In contrast, treatment with taxol alone did not reduce tumour hypoxia ( Figure 4C) . Analysis of the distribution of pericytes (NG2 + ) and endothelial cells (CD31+) in tumours that developed in AB0023-treated mice revealed a statistically significant increase of endothelial cells in close association with pericytes following AB0023 treatment (Figure 4D and E; Supplementary movies, available at Carcinogenesis Online).
To confirm our observation that AB0023 treatment improved the perfusion of these tumours, we conducted an independent SKOV-3 xenograft study in which we treated tumours with 15 mg/kg of the AC-1 control antibody or AB0023 for 50 days and injected fluorescent Hoechst 33342 dye just prior to tumour excision (29, 30) . We found that AB0023 caused a significant improvement in perfusion compared with tumours of control animals, evidenced by increased numbers of CD31-positive vessels associated with areas of Hoechst dye extravasation ( Figure 5A and C) . We confirmed the effect of AB0023 treatment on increased pericyte coverage of tumour-associated microvessels by counting an increased number of NG2-stained cells closely associated with CD31-stained endothelial cells in histological sections ( Figure 5A and B) .
Because inhibition of VEGF signaling was reported to induce normalization of tumour blood vessels (22), we evaluated whether Figure 5C , available at Carcinogenesis Online), suggesting that inhibition of LOXL2 does not directly influence VEGF expression in the tumour cells. We also determined whether AB0023 inhibits VEGF-induced phosphorylation of ERK1/2 in endothelial cells. Indeed, we observed that the VEGF-induced phosphorylation of ERK1/2 in endothelial cells pre-incubated for 24 h with AB0023 is inhibited by about 50% (Supplementary Figure 5D , available at Carcinogenesis Online), suggesting that inhibition of LOXL2 activity may inhibit angiogenesis in part by affecting VEGF signaling in endothelial cells.
We next examined the effects of AB0023 administration on the development of the highly angiogenic tumours that are derived from murine LLC cells. In agreement with the results described above, we found that intraperitoneal injection of AB0023 (15 mg/ kg) significantly reduced the concentration of microvessels in the tumours ( Figure 6A ). As in the SKOV-3 tumours, the reduction in microvessel density did not suffice to inhibit tumour development (data not shown). Interestingly, we observed that LLC tumours of mice treated with AB0023 contained fewer blood vessels of large diameter compared with tumours from control-treated mice ( Figure 6A, arrows) . Ultrasonography using a contrast agent to highlight perfused vasculature confirmed the presence of multiple large diameter blood vessels in control tumours. In contrast, almost no large diameter vessels were detected in tumours from AB0023-treated mice ( Figure 6B, arrows) . As in the SKOV-3 study, the perfusion of LLC tumours from AB0023-treated mice was improved compared with control-treated mice. Tumours in AB0023-treated mice filled more rapidly with a blood borne contrast agent following flash clearance of microbubble contrast agent from the tumour blood vessels using a high energy pulse of ultrasound ( Figure 6C ). These results indicate that LOXL2 overexpression in tumours contributes to the dysfunction of tumourassociated blood vessels and suggest that the vascular normalizing properties of LOXL2 inhibitors may improve the efficacy of chemotherapeutic agents. . Each data point shown is the average of three representative ×10 fields taken from two-step sections separated by 300 μm (six fields per plug). (C) Quantification of the average area of cells staining with an antibody directed against CD34 in 5 μm paraffin sections cut from plugs excised from an independent Matrigel plug study in which mice were treated with vehicle control (three mice, each with two plugs), AC-1 non-targeting antibody control (30 mg/ kg) (five plugs from three mice) or AB0023 (30 mg/kg) (five plugs from three mice). Each data point shown is the average of three representative ×10 fields taken from one representative section from each plug. (D) Cells contained in Matrigel plugs from vehicle and AB0023 (AB23)-treated animals were recovered and subjected to analysis by FACS as described using the designated antibody combinations. Each group contained three mice inoculated with six plugs.
Discussion
LOXL2 is highly expressed in several types of highly invasive malignant tumours including breast cancer (3, 12, 42) , stomach cancer (6) and pancreatic cancer (12) and promotes tumour cells invasiveness and tumour metastasis (3, 6, 12, 43) . Our previous work examined LOXL2 expression and function in lung and liver fibrosis and desmoplastic tumours containing a fibroblast-rich stroma. In these studies, the predominant source of LOXL2 was fibroblasts, and LOXL2 likely participated in the activation of these cells by increasing local tension via cross-linking of fibrillar collagens (12) . In these studies, LOXL2 expression was also observed to be induced in blood vessels in or adjacent to diseased tissue, and treatment with the LOXL2-neutralizing antibody AB0023 resulted in a decrease in the concentration of CD31-positive endothelial cells in a primary tumour model (12) . However, this anti-angiogenic activity was not further explored to determine whether this resulted from changes in the fibrotic milieu or from direct action on the neovasculature. Other studies have suggested that LOXL2 may be involved directly in the regulation of angiogenesis (19, 20) . Indeed, LOXL2 enhances the deposition of elastic fibres in the wall of blood vessels (18) and regulates developmental angiogenesis (20) . Here we sought to examine in greater depth the role of LOXL2 in tumour angiogenesis by using a combination of in vitro assays and models of predominantly non-desmoplastic but highly angiogenic tumours.
We have confirmed that LOXL2 plays a direct role in angiogenesis through the use of in vitro and in vivo angiogenesis assays. Both reduction of LOXL2 expression in endothelial cells with shRNAs and inhibition of endothelial cell-derived LOXL2 using AB0023 disrupted endothelial cell migration and network assembly. AB0023 administration also reduced bFGF-induced angiogenesis in in vivo Matrigel plug angiogenesis assays (33, 34) . Interestingly, we found that AB0023 inhibited the recruitment of bone-marrow-derived cell populations that have previously been found to enhance tumour angiogenesis (35, 36) , suggesting that the anti-angiogenic effects of AB0023 may also be mediated in part by inhibiting the recruitment or establishment of this cell population. These observations are in agreement with previous findings where tumour-derived lysyl oxidases induced the recruitment of bone marrow cells to distant sites (44, 45) and suggest that LOXL2 is required for critical events in tumour angiogenesis.
We next evaluated whether inhibition of LOXL2 affected tumour angiogenesis in two non-desmoplastic tumour models (SKOV-3 and LLC) to differentiate as much as possible direct anti-angiogenic effects from those that were due to effects on fibroblast activation. SKOV-3-derived tumours expressed LOXL2 in tumour-associated blood vessels and also in regions that resemble the glomerular microvascular proliferations, which have also been identified in some human ovarian metastases (46) . Although LOXL2 protein was also observed in a subset of tumour cells and in a few limited regions of α-smooth muscle actin-negative collagen-rich stroma, the most prevalent expression was observed in tumour-associated vasculature. LOXL2 was also highly expressed in the vasculature of LLCderived tumours, which have been used extensively to study tumour angiogenesis (47) . As in SKOV-3 tumours, limited populations of tumour cells and fibroblasts within the tumours expressed LOXL2, but the most prevalent and strongest LOXL2 signal was associated with tumour vasculature. Although AB0023 treatment significantly reduced the density of microvessels in tumours that develop from both SKOV-3 and LLC cells, the effects of LOXL2 inhibition did not result in a reduction of tumour growth. Moreover, in spite of the reduced microvascular density, tumour perfusion was improved.
These data are consistent with AB0023-mediated enhancement of the anti-tumourigenic effects of taxol, a result that is reminiscent of the synergistic effects previously observed between the anti-VEGFR2 inhibitory antibody DC101 and chemotherapeutic agents. DC101 administration in preclinical xenograft tumour models resulted in an anti-angiogenic effect that was accompanied by the normalization of leaky and disorganized intra-tumoural blood vessels. This normalization, characterized by reduced vessel number, increased pericyte coverage and enhanced perfusion, enabled better delivery of chemotherapeutic agents to the tumour cells and thereby increased the efficacy of the chemotherapeutic treatment (22, 40) . When we investigated whether LOXL2 inhibition had similar effects on tumour vessels, we found that AB0023 treatment did in fact induce the recruitment of pericytes to tumour vessels, increase the proportion of mature blood vessels, decrease tumour hypoxia and enhance the perfusion of tumours. These data suggest that the anti-proliferative effects observed when AB0023 was administered in combination with taxol were due to the normalization of the tumour vasculature and improved delivery of taxol.
LOXL2 over-expression induces the accumulation of highly crosslinked abnormally packed collagen fibres in tumours, indicating that LOXL2 modifies the tumour ECM similarly to LOX (3). Recent findings indicate that LOX-induced 'stiffening' of the ECM of tumours can by itself promote tumour cells invasiveness (13) . Similar mechanisms may also operate to increase migration and formation of angiogenic sprouts during tumour angiogenesis. The ECM and modification of its constituents are known to play a crucial role in vascular neogenesis. It was suggested that endothelial cell sprouting is triggered by degradation of the vascular basement membrane and exposure of endothelial cells to interstitial collagen I (17) . Fibrillar collagen I, a known LOXL2 substrate, acting through integrins, has been shown to elicit morphological changes in endothelial cells and to promote endothelial assembly into vascular structures (17) . Furthermore, LOXL2 is known to induce hypoxia-driven deposition of collagen IV by endothelial cells (20) , suggesting that LOXL2 could promote angiogenesis by acting directly or indirectly to modify the vascular basement membrane.
We have recently shown that stimulation of keratinocytes with a point mutated LOXL2 lacking enzyme activity can regulate gene expression by utilizing unidentified putative LOXL2 receptors (48) . Because the vessel normalizing effects of AB0023 are reminiscent of the effects of antibodies that inhibit VEGF signaling, we evaluated whether AB0023 can affect VEGF expression in SKOV-3 cells. However, AB0023 did not seem to affect endogenous VEGF production in these cells. On the other hand, AB0023 was able to inhibit partially VEGFinduced phosphorylation of ERK1/2 in endothelial cells that were preincubated with AB0023, suggesting that part of the anti-angiogenic and vessel normalizing effect of AB0023 may result from inhibition of VEGF-induced signalling in endothelial cells. The mechanism by which AB0023 affects VEGF signaling may be the result of a direct effect on LOXL2 signaling mediated by putative LOXL2 receptors (48) . Alternatively, inhibition of LOXL2 activity may indirectly affect VEGF signal transduction, and possibly signal transduction by additional angiogenic factors, through inhibition of the LOXL2-induced remodelling of the basement membrane produced by endothelial cells (20) . These possibilities will need to be further examined in the future.
Taken together, our data support a role for LOXL2 as a contributor to neovascularization in angiogenic diseases. We have previously shown that the expression of LOXL2 is low in normal tissues (12) and that targeting LOXL2 with AB0023 in vivo has no obvious detrimental effects on the cardiovascular system, on highly vascularized healthy tissues or on wound healing in a murine model (12) . Our results suggest that inhibition of LOXL2 could be beneficial for the treatment of angiogenic diseases and that LOXL2 inhibitors could be used to enhance the anti-tumourigenic effects of chemotherapeutics in highly vascularized tumours, such as ovarian carcinoma.
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